TherapeuticsMD, Inc. (TXMD) shareholders
Close on Nov 17, 2026Market cap $22.11MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Baselake Partners, LP Joint filing with Baselake Management, LLC (6.80%), David Paolella (6.80%) | 790,703 | 6.80% | 13G (passive) amendment | Jun 30, 2026 |
| Clearline Capital LP Joint filing with Clearline Capital, LLC (5.50%), Marc Majzner (5.50%) | 635,222 | 5.50% | 13G (passive) | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TXMD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rubric Capital Management LP | 1,192,191 | 10.30% | $2.63M | – | 0.02% |
| Clearline Capital LP | 635,222 | 5.49% | $1.40M | – | 0.08% |
| Vanguard Capital Management LLC | 353,697 | 3.06% | $781.67K | – | 0.00% |
| Tejara Capital Ltd | 344,482 | 2.98% | $761.31K | −1,370 | 0.31% |
| ADAR1 Capital Management, LLC | 342,447 | 2.96% | $756.81K | +133,237 | 0.03% |
| Renaissance Technologies LLC | 146,599 | 1.27% | $323.98K | +399 | 0.00% |
| Morgan Stanley | 129,217 | 1.12% | $285.57K | – | 0.00% |
| BlackRock, Inc. | 115,145 | 0.99% | $254.47K | – | 0.00% |
| Geode Capital Management, LLC | 105,849 | 0.91% | $233.99K | −3,968 | 0.00% |
| Citadel Advisors LLC | 86,095 | 0.74% | $190.27K | +17,781 | 0.00% |
| Vanguard Fiduciary Trust Co | 63,831 | 0.55% | $141.07K | – | 0.00% |
| State Street Corp | 30,100 | 0.26% | $66.52K | – | 0.00% |
| XTX Topco Ltd | 21,246 | 0.18% | $46.95K | −6,241 | 0.00% |
| Dimensional Fund Advisors LP | 19,719 | 0.17% | $43.58K | +9,013 | 0.00% |
| Northern Trust Corp | 18,556 | 0.16% | $41.01K | +2,463 | 0.00% |
| Bridgeway Capital Management, LLC | 17,000 | 0.15% | $37.57K | – | 0.00% |
| Osaic Holdings, Inc. | 15,198 | 0.13% | $33.59K | +15,045 | 0.00% |
| Hrt Financial LP | 14,727 | 0.13% | $32.00K | New | 0.00% |
| Vanguard Global Advisers, LLC | 4,937 | 0.04% | $10.91K | – | 0.00% |
| UBS Group AG | 4,660 | 0.04% | $10.30K | +4,329 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 45 | 4M | 31.7% | 5 / 11 | 4 / 7 | 0M | 0M |
| Q1 2026 | 49 | 4M | 34.0% | 10 / 7 | 9 / 3 | 1M | 0M |
| Q4 2025 | 44 | 3M | 29.2% | 4 / 7 | 8 / 6 | 0M | 0M |
| Q3 2025 | 46 | 3M | 28.5% | 7 / 4 | 11 / 3 | 0M | 0M |
| Q2 2025 | 42 | 3M | 28.1% | 2 / 9 | 8 / 2 | 0M | 0M |
| Q1 2025 | 42 | 3M | 28.9% | 5 / 7 | 7 / 4 | 0M | 0M |
| Q4 2024 | 41 | 4M | 30.5% | 8 / 3 | 6 / 4 | 0M | 0M |
| Q3 2024 | 37 | 3M | 29.2% | 5 / 3 | 5 / 5 | 0M | 0M |
| Q2 2024 | 38 | 3M | 29.5% | 3 / 6 | 11 / 8 | 0M | 0M |
| Q1 2024 | 43 | 4M | 31.5% | 8 / 7 | 7 / 4 | 0M | 0M |
| Q4 2023 | 39 | 3M | 29.2% | 6 / 6 | 10 / 3 | 0M | 0M |
| Q3 2023 | 36 | 3M | 25.8% | 4 / 7 | 6 / 10 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
12 funds held TXMD in Q2 2026, 75% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TXMD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 244,317 | 2.11% | $539.94K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 109,380 | 0.95% | $241.73K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 65,183 | 0.56% | $139.49K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 17,000 | 0.15% | $37.57K | 0.03% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 15,320 | 0.13% | $32.78K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 14,835 | 0.13% | $31.75K | 0.00% | May 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 4,826 | 0.04% | $9.80K | 0.00% | Jul 31, 2026 |
| Dimensional US Sustainability Core 1 ETF | 3,612 | 0.03% | $7.33K | 0.00% | Jul 31, 2026 |
| The Gabelli ABC Fund | 3,600 | 0.03% | $7.96K | 0.00% | Jun 30, 2026 |
| Dimensional US Core Equity 1 ETF | 3,076 | 0.03% | $6.24K | 0.00% | Jul 31, 2026 |
| Enterprise Mergers and Acquisitions Fund | 1,000 | 0.01% | $2.21K | 0.00% | Jun 30, 2026 |
| Diversified Equity Alpha Master Portfolio | 745 | 0.01% | $1.65K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Marlan D. Walker | Chief Executive Officer | 73,639 | 0.64% | Nov 5, 2025 |
| Tommy G. Thompson | Director | 37,512 | 0.32% | Dec 29, 2025 |
| Cooper C. Collins | Director | 60,516 | 0.52% | Nov 5, 2025 |
| Gail K. Naughton | Director | 8,500 | 0.07% | Nov 5, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Tommy G. Thompson Director | Dec 23, 2025 | Buy | +8,400 | $1.67 | $14.03K | 23,179 |
| Tommy G. Thompson Director | Apr 14, 2025 | Buy | +325 | $1.00 | $325 | 14,779 |
| Marlan D. Walker Chief Executive Officer | Apr 14, 2025 | Buy | +490 | $1.00 | $490 | 73,639 |
| Marlan D. Walker Chief Executive Officer | Apr 10, 2025 | Buy | +1,167 | $0.86 | $1.00K | 73,149 |
| Marlan D. Walker Chief Executive Officer | Apr 9, 2025 | Buy | +1,136 | $0.87 | $988 | 71,982 |
| Tommy G. Thompson Director | Feb 18, 2025 | Option exercise | +8,500 | – | – | 14,454 |
| Gail K. Naughton Director | Feb 18, 2025 | Option exercise | +8,500 | – | – | 8,500 |
| Cooper C. Collins Director | Feb 18, 2025 | Option exercise | +8,500 | – | – | 60,516 |
| Marlan D. Walker Chief Executive Officer | Feb 18, 2025 | Option exercise | +3,467 | – | – | 66,032 |
| Marlan D. Walker Chief Executive Officer | Feb 18, 2025 | Option exercise | +2,311 | – | – | 68,343 |
| Marlan D. Walker Chief Executive Officer | Feb 18, 2025 | Option exercise | +1,733 | – | – | 70,846 |
| Marlan D. Walker Chief Executive Officer | Feb 18, 2025 | Option exercise | +770 | – | – | 69,113 |
| Cooper C. Collins Director | Aug 22, 2024 | Buy | +4,094 | $1.73 | $7.08K | 52,016 |
| Cooper C. Collins Director | Aug 21, 2024 | Buy | +1,200 | $1.70 | $2.04K | 47,922 |
| Marlan D. Walker Chief Executive Officer | Dec 7, 2023 | Sale | −4,550 | $2.24 | $10.19K | 62,565 |
| Marlan D. Walker Chief Executive Officer | Dec 6, 2023 | Sale | −14,500 | $2.31 | $33.50K | 67,115 |
| Marlan D. Walker Chief Executive Officer | Dec 5, 2023 | Option exercise | +70,000 | – | – | 81,615 |
| David Efraim Rosen 10% owner | Nov 15, 2023 | Award | +877,192 | $2.28 | $2.00M | 2,946,908 |
| Joseph Ziegler Principal Financial Officer | Aug 17, 2023 | Award | +7,500 | – | – | 7,500 |
| David Efraim Rosen Director, 10% owner | Jun 28, 2023 | Award | +312,525 | $3.68 | $1.15M | 2,069,716 |
| Marlan D. Walker Chief Executive Officer | Apr 26, 2023 | Sale | −692 | $3.64 | $2.52K | 11,615 |
| Marlan D. Walker Chief Executive Officer | Apr 26, 2023 | Option exercise | +1,010 | – | – | 14,041 |
| Marlan D. Walker Chief Executive Officer | Apr 26, 2023 | Option exercise | +1,734 | – | – | 12,307 |
| Michael C. Donegan Prin. Fin. and Acctg. Officer | Apr 12, 2023 | Option exercise | +50,000 | – | – | 61,853 |
| Marlan D. Walker Chief Executive Officer | Apr 12, 2023 | Option exercise | +3,030 | – | – | 8,999 |
| Marlan D. Walker Chief Executive Officer | Apr 12, 2023 | Option exercise | +1,010 | – | – | 10,009 |
| Marlan D. Walker Chief Executive Officer | Apr 12, 2023 | Option exercise | +1,734 | – | – | 11,743 |
| Marlan D. Walker Chief Executive Officer | Apr 12, 2023 | Option exercise | +1,734 | – | – | 13,477 |
| Marlan D. Walker Chief Executive Officer | Apr 12, 2023 | Sale | −1,170 | $3.65 | $4.27K | 12,307 |
| Michael C. Donegan Prin. Fin. and Acctg. Officer | Jan 27, 2023 | Sale | −49 | $5.09 | $249 | 11,853 |
| Michael C. Donegan Prin. Fin. and Acctg. Officer | Jan 26, 2023 | Option exercise | +1,140 | – | – | 13,550 |
| Michael C. Donegan Prin. Fin. and Acctg. Officer | Jan 26, 2023 | Sale | −1,648 | $5.08 | $8.37K | 11,902 |
| Michael C. Donegan Prin. Fin. and Acctg. Officer | Jan 26, 2023 | Option exercise | +2,400 | – | – | 10,010 |
| Michael C. Donegan Prin. Fin. and Acctg. Officer | Jan 26, 2023 | Option exercise | +2,400 | – | – | 12,410 |
| Michael C. Donegan Prin. Fin. and Acctg. Officer | Jan 24, 2023 | Sale | −7 | $5.31 | $37 | 7,610 |
| Michael C. Donegan Prin. Fin. and Acctg. Officer | Jan 23, 2023 | Option exercise | +519 | – | – | 6,519 |
| Michael C. Donegan Prin. Fin. and Acctg. Officer | Jan 23, 2023 | Option exercise | +380 | – | – | 4,934 |
| Michael C. Donegan Prin. Fin. and Acctg. Officer | Jan 23, 2023 | Option exercise | +1,066 | – | – | 6,000 |
| Michael C. Donegan Prin. Fin. and Acctg. Officer | Jan 23, 2023 | Sale | −1,302 | $5.34 | $6.95K | 7,617 |
| Michael C. Donegan Prin. Fin. and Acctg. Officer | Jan 23, 2023 | Option exercise | +2,400 | – | – | 8,919 |
| Capital Management LP Rubric Director, 10% owner | Dec 30, 2022 | Returned to company | −29,000 | $1333.00 | $38.66M | 0 |
| Capital Management LP Rubric 10% owner | Dec 30, 2022 | Sale | −29,000 | $1333.00 | $38.66M | 0 |
| Capital Management LP Rubric 10% owner | Dec 9, 2022 | Buy | +14,825 | $6.09 | $90.28K | 1,757,191 |
| Brian Bernick Co-Chief Executive Officer | Dec 9, 2022 | Sale | −320 | $6.31 | $2.02K | 3,872 |
| Marlan D. Walker Chief Executive Officer | Dec 8, 2022 | Gift | −716 | – | – | 5,969 |
| David Efraim Rosen 10% owner | Dec 8, 2022 | Buy | +300 | $5.83 | $1.75K | 1,742,366 |
| David Efraim Rosen 10% owner | Dec 7, 2022 | Buy | +20,113 | $5.66 | $113.84K | 1,742,066 |
| Gail K. Naughton Director | Dec 7, 2022 | Sale | −3,922 | $5.26 | $20.63K | 0 |
| Marlan D. Walker General Counsel | Dec 6, 2022 | Option exercise | +1,010 | – | – | 6,189 |
| Marlan D. Walker General Counsel | Dec 6, 2022 | Option exercise | +388 | – | – | 7,733 |
| Marlan D. Walker General Counsel | Dec 6, 2022 | Sale | −1,048 | $4.95 | $5.19K | 6,685 |
| Marlan D. Walker General Counsel | Dec 6, 2022 | Option exercise | +1,156 | – | – | 7,345 |
| Michael C. Donegan Interim CFO/CAO/VP of Finance | Dec 6, 2022 | Option exercise | +2,300 | – | – | 4,288 |
| Michael C. Donegan Interim CFO/CAO/VP of Finance | Dec 6, 2022 | Option exercise | +380 | – | – | 4,668 |
| Michael C. Donegan Interim CFO/CAO/VP of Finance | Dec 6, 2022 | Option exercise | +534 | – | – | 5,202 |
| Michael C. Donegan Interim CFO/CAO/VP of Finance | Dec 6, 2022 | Sale | −910 | $4.78 | $4.35K | 4,554 |
| Michael C. Donegan Interim CFO/CAO/VP of Finance | Dec 6, 2022 | Option exercise | +262 | – | – | 5,464 |
| Mark A. Glickman Co-Chief Executive Officer | Dec 6, 2022 | Option exercise | +1,734 | – | – | 1,734 |
| Mark A. Glickman Co-Chief Executive Officer | Dec 6, 2022 | Sale | −440 | $4.92 | $2.16K | 1,294 |
| Brian Bernick Co-Chief Executive Officer | Dec 6, 2022 | Sale | −935 | $4.92 | $4.60K | 4,192 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of TherapeuticsMD's stock actually held short. Settlement fails (shares not delivered on time) peaked at 535 shares on Oct 13, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Marlan D. Walker Officer | Dec 6, 2023 | 28,134 | $70.06K | Dec 6, 2023 | RSU |
See a number that looks wrong?